In this issue:
2012 recommendations of the International Antiviral Society
RPV vs. EFV with TDF/FTC in treatment-naive HIV-1
Coformulated EVG/COBI/FTC/TDF
Once daily DTG in ART-naive HIV
LLV and rebound risk with HAART
LLV virological failure risk
DRV/r ±2 NRTIs
Effect of COBI on GFR
Long-term RAL in treatmentnaïve HIV-1
Please login below to download this issue (PDF)